Regarding the vaccine-induced humoral immunogenicity after 6 months from the completed vaccination, we found that the anti-RBD antibody response was still detectable in all HCWs and in the majority of RA patients, although the titer was significantly reduced in those under TNF-α inhibitors and CTLA-4-Ig compared to HCWs. This evidence concerns the gene CTLA4 and rheumatoid arthritis.